Urology > 2006 > 68 > Supplement > 180
MP-19: Adrenal/kidney/ureter
A multicenter, randomized, phase III trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma
Source
Identifiers
journal ISSN : | 0090-4295 |
DOI | 10.1016/j.urology.2006.08.573 |